tetano
Editor, Senior Moderator
Cell Rep
. 2022 Oct 5;111554.
doi: 10.1016/j.celrep.2022.111554. Online ahead of print.
A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses
Alexandra Tauzin[SUP] 1 [/SUP], Shang Yu Gong[SUP] 2 [/SUP], Debashree Chatterjee[SUP] 3 [/SUP], Shilei Ding[SUP] 3 [/SUP], Mark M Painter[SUP] 4 [/SUP], Rishi R Goel[SUP] 5 [/SUP], Guillaume Beaudoin-Bussières[SUP] 1 [/SUP], Lorie Marchitto[SUP] 1 [/SUP], Marianne Boutin[SUP] 1 [/SUP], Annemarie Laumaea[SUP] 1 [/SUP], James Okeny[SUP] 6 [/SUP], Gabrielle Gendron-Lepage[SUP] 3 [/SUP], Catherine Bourassa[SUP] 3 [/SUP], Halima Medjahed[SUP] 3 [/SUP], Guillaume Goyette[SUP] 3 [/SUP], Justine C Williams[SUP] 7 [/SUP], Yuxia Bo[SUP] 6 [/SUP], Laurie Gokool[SUP] 3 [/SUP], Chantal Morrisseau[SUP] 3 [/SUP], Pascale Arlotto[SUP] 3 [/SUP], Renée Bazin[SUP] 8 [/SUP], Judith Fafard[SUP] 9 [/SUP], Cécile Tremblay[SUP] 1 [/SUP], Daniel E Kaufmann[SUP] 10 [/SUP], Gaston De Serres[SUP] 11 [/SUP], Jonathan Richard[SUP] 1 [/SUP], Marceline Côté[SUP] 6 [/SUP], Ralf Duerr[SUP] 12 [/SUP], Valérie Martel-Laferrière[SUP] 1 [/SUP], Allison R Greenplate[SUP] 5 [/SUP], E John Wherry[SUP] 4 [/SUP], Andrés Finzi[SUP] 13 [/SUP]
Affiliations
Abstract
Due to the recrudescence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections worldwide, mainly caused by the Omicron variant of concern (VOC) and its sub-lineages, several jurisdictions are administering an mRNA vaccine boost. Here, we analyze humoral responses induced after the second and third doses of an mRNA vaccine in naive and previously infected donors who received their second dose with an extended 16-week interval. We observe that the extended interval elicits robust humoral responses against VOCs, but this response is significantly diminished 4 months after the second dose. Administering a boost to these individuals brings back the humoral responses to the same levels obtained after the extended second dose. Interestingly, we observe that administering a boost to individuals that initially received a short 3- to 4-week regimen elicits humoral responses similar to those observed in the long interval regimen. Nevertheless, humoral responses elicited by the boost in naive individuals do not reach those present in previously infected vaccinated individuals.
Keywords: COVID-19; CP: Immunology; SARS-CoV-2; coronavirus; humoral responses; long interval; spike glycoproteins; third mRNA vaccine dose; variants of concern.
. 2022 Oct 5;111554.
doi: 10.1016/j.celrep.2022.111554. Online ahead of print.
A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses
Alexandra Tauzin[SUP] 1 [/SUP], Shang Yu Gong[SUP] 2 [/SUP], Debashree Chatterjee[SUP] 3 [/SUP], Shilei Ding[SUP] 3 [/SUP], Mark M Painter[SUP] 4 [/SUP], Rishi R Goel[SUP] 5 [/SUP], Guillaume Beaudoin-Bussières[SUP] 1 [/SUP], Lorie Marchitto[SUP] 1 [/SUP], Marianne Boutin[SUP] 1 [/SUP], Annemarie Laumaea[SUP] 1 [/SUP], James Okeny[SUP] 6 [/SUP], Gabrielle Gendron-Lepage[SUP] 3 [/SUP], Catherine Bourassa[SUP] 3 [/SUP], Halima Medjahed[SUP] 3 [/SUP], Guillaume Goyette[SUP] 3 [/SUP], Justine C Williams[SUP] 7 [/SUP], Yuxia Bo[SUP] 6 [/SUP], Laurie Gokool[SUP] 3 [/SUP], Chantal Morrisseau[SUP] 3 [/SUP], Pascale Arlotto[SUP] 3 [/SUP], Renée Bazin[SUP] 8 [/SUP], Judith Fafard[SUP] 9 [/SUP], Cécile Tremblay[SUP] 1 [/SUP], Daniel E Kaufmann[SUP] 10 [/SUP], Gaston De Serres[SUP] 11 [/SUP], Jonathan Richard[SUP] 1 [/SUP], Marceline Côté[SUP] 6 [/SUP], Ralf Duerr[SUP] 12 [/SUP], Valérie Martel-Laferrière[SUP] 1 [/SUP], Allison R Greenplate[SUP] 5 [/SUP], E John Wherry[SUP] 4 [/SUP], Andrés Finzi[SUP] 13 [/SUP]
Affiliations
- PMID: 36244343
- DOI: 10.1016/j.celrep.2022.111554
Abstract
Due to the recrudescence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections worldwide, mainly caused by the Omicron variant of concern (VOC) and its sub-lineages, several jurisdictions are administering an mRNA vaccine boost. Here, we analyze humoral responses induced after the second and third doses of an mRNA vaccine in naive and previously infected donors who received their second dose with an extended 16-week interval. We observe that the extended interval elicits robust humoral responses against VOCs, but this response is significantly diminished 4 months after the second dose. Administering a boost to these individuals brings back the humoral responses to the same levels obtained after the extended second dose. Interestingly, we observe that administering a boost to individuals that initially received a short 3- to 4-week regimen elicits humoral responses similar to those observed in the long interval regimen. Nevertheless, humoral responses elicited by the boost in naive individuals do not reach those present in previously infected vaccinated individuals.
Keywords: COVID-19; CP: Immunology; SARS-CoV-2; coronavirus; humoral responses; long interval; spike glycoproteins; third mRNA vaccine dose; variants of concern.